Eli Lilly announced on Mar. 11 that it will invest $3 billion into its China operations over the next decade as it prepares for a potential approval of its oral obesity drug, orforglipron.
The investment is intended to increase manufacturing capacity and establish a local production chain for the weight loss pill. According to an automated translation of Lilly's announcement, the funds will also help meet domestic demand, create jobs, and support the development of China's biotech industry.
Lilly said it plans to use the "talent advantages" at its Suzhou plant and work with external local partners as part of this expansion. The company has already begun preparing for orforglipron's launch in other markets; in the United States, the drug is under review by the Food and Drug Administration with a target action date of April 10. Lilly reported having $1.5 billion worth of orforglipron ready as of Dec. 31, 2025.
The company filed a regulatory application for orforglipron in China at the end of 2025 but did not specify when a decision might be made.
Other major pharmaceutical companies have also increased their investments in China recently. AstraZeneca pledged $15 billion through the end of the decade to expand its capabilities in cell therapies and radioconjugates, while Pfizer and Sanofi have each signed multi-million dollar agreements with Chinese firms.
